C12N 2770/32632
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2770/32632 (Use of virus as therapeutic agent, other than vaccine) appears on 13 US grants and 20 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 20
- Assignees
- 4
- Inventors
- 22
- Latest grant
- 31 Dec 2024
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 2 |
| 2019 | 1 | 2 |
| 2020 | 2 | 2 |
| 2021 | 1 | 3 |
| 2022 | 2 | 1 |
| 2023 | 1 | 0 |
| 2024 | 1 | 2 |
| 2025 | 0 | 1 |
By publication year.
Recent patents
- Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer31 Dec 2024US 12,178,869 B2Codagenix Inc.
- Oncolytic poliovirus for human tumors14 Nov 2023US 11,813,298 B2Duke University
- Oncolytic poliovirus for human tumors9 Aug 2022US 11,406,677 B2Duke University
- Compositions and methods for activating antigen presenting cells with chimeric poliovirus17 May 2022US 11,331,343 B2Duke University
- Treating cancer with viral nucleic acid9 Feb 2021US 10,913,775 B2Mayo Foundation for Medical Education and Research
- Neoadjuvant cancer treatment31 Jul 2025US 2025/0241969 A1Duke University
- Combination Treatment19 Dec 2024US 2024/0415906 A1Duke University
- Methods for determining tumor immune status6 Jun 2024US 2024/0180984 A1Duke University
- Oncolytic Poliovirus for Human Tumors27 Oct 2022US 2022/0339223 A1Duke University
- Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer29 Jul 2021US 2021/0228705 A1Codagenix Inc.
Most cited
By later US patents
- Method of detecting the presence of CD155 for diagnosis of cancer and to determine treatment35US 6,518,033 B1The Research Foundation of State University of New York · 2003
- Recombinant poliovirus for the treatment of cancer13US 6,264,940 B1The Research Foundation of State University of New York · 2001
- Recombinant poliovirus for the treatment of cancer9US 6,464,972 B1The Research Foundation of State University of New York · 2002
- Recombinant poliovirus for the treatment of cancer6US 7,147,848 B2The Research Foundation of State University of New York · 2006
- Oncolytic poliovirus for human tumors2US 10,398,743 B2Duke University · 2019